4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Catalog No.: 
ACMFGQ641
CAS No.: 
19171-19-8
Molecular Formula: 
C13H11N3O4
Molecular Weight: 
273.07
4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%
100g98%
500g98%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
IUPAC Name4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
MDL No.MFCD12756407
Molecular FormulaC13H11N3O4
Molecular Weight273.07
SMILESNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
InChI KeyUVSMNLNDYGZFPF-UHFFFAOYSA-N
SynonymPomalidomide (CC-4047) | POMALIDOMIDE [EMA EPAR] | POMALIDOMIDE [WHO-DD] | SCHEMBL369172 | BCP02890 | DTXCID801323473 | Pomalyst | IMID-3 | 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | LACTONE | SR-01000941573 | AC-26970 | MLS006011261 | AKOS0
CAS No.19171-19-8
PubChem CID134780

Synthetic Route by SureRoute

1. ACMFGQ641 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFMEV869 route compound structure diagram
    ACFMEV86919171-18-7In Stock
  2. Then
  3. ACMFGQ641 route product structure diagram
    ACMFGQ64119171-19-8In Stock
Inquiry

2. ACMFGQ641 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACDTQJ324 route compound structure diagram
    ACDTQJ3247447-41-8In Stock
  2. Plus
  3. ACQVBJ321 route compound structure diagram
    ACQVBJ32124666-56-6In Stock
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACMFGQ641 route product structure diagram
    ACMFGQ64119171-19-8In Stock
Inquiry

3. ACMFGQ641 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMFGQ641 route product structure diagram
    ACMFGQ64119171-19-8In Stock
Inquiry

Comments (0)